CONTACT

Dr Richard Shaffer

Dr Richard Shaffer initially became interested in treating Dupuytren’s disease as a result of his experience treating skin cancers with radiotherapy, and an on-going interest in using radiotherapy as a treatment for benign conditions.

He created The Dupuytren’s Practice in order to provide people in the UK with a non-invasive alternative to other treatments for people who suffer from benign conditions such as Ledderhose disease, Plantar fasciitis and early stage Dupuytren’s disease. He has acted as a specialist advisor for NICE (National Institute for Health and Clinical Excellence) on the issue of radiotherapy for Dupuytren’s disease, and acts as a medical expert on the Dupuytren’s Disease Support Group and The British Dupuytren’s Society.

He is a clinical oncologist who uses radiotherapy and chemotherapy to treat brain tumours, skin cancer and bladder and prostate cancer. He has a specialist interest in implementing new radiotherapy technology, including IMRT, IGRT, RapidArc and Intracranial Stereotactic Radiotherapy.

He has previously served as Clinical Lead for Radiotherapy in Guildford, and chaired the Radiotherapy Strategy Group and Network Radiotherapy Group. He also chaired the Radiotherapy Technology Development Group, and has led the Brain Tumour Working Group since January 2010. He served on the Royal College of Radiologists Working Group looking into the use of radiotherapy for benign conditions, leading to a consensus document on the issue. He has also been the principal investigator on several treatment studies in brain tumours, prostate cancer and skin cancer. He is currently supervising a clinical fellow in a programme of clinical and lab-based radiobiological research.

Prior to working at Royal Surrey County Hospital, Dr Richard Shaffer undertook his oncology (cancer treatment) training in London and went on to complete a Clinical Fellowship in Radiation Oncology (treatment of cancer with radiotherapy) in Vancouver, Canada. Whilst in Canada he completed a number of research projects in technical radiotherapy, including the comparison of conventional IMRT with volumetric modulated arc therapy (VMAT) and RapidArc in several disease sites such as prostate, breast, high-grade glioma, and paediatric tumours. Dr Shaffer has presented and been published widely in the oncology field.

Dr Richard Shaffer is also a keen pianist and has played at various festivals and venues including Ronnie Scott’s Jazz Club in London. He particularly enjoys travelling and spending time with his family.

Selected Publications

Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Stephanie McKeown, Paul Hatfield, Robin Prestwich, Richard Shaffer, Roger Taylor. British Journal of Radiology 2015; 88: 20150405.

Radiotherapy for Benign Disease: Current Evidence, Benefits and Risks.
Taylor RE, Hatfield P, McKeown SR, Prestwich RJ, Shaffer R.
Clin Oncol (R Coll Radiol). 2015 Aug;27(8):433-5.

A review of the use of radiotherapy in the UK for the treatment of benign clinical conditions and benign tumours. Royal College of Radiologists 2015.

A radiotherapy planning study for RapidArc, intensity modulated radiotherapy, three-dimensional conformal radiotherapy and parallel opposed beams in the treatment of pediatric retropenitoneal tumors. Richard Shaffer, Emily Vollans, Rosie Vellani, Margaret Welsh, Vitali Moiseenko, Karen Goddard, Pediatric Blood and Cancer 2011 Jan; 56 (1):16-23

A comparison of volumetric modulated arc therapy (VMAT) and conventional intensity modulated radiotherapy (IMRT) for front and temporal high-grade gliomas. Richard Shaffer, Alan M Nichol, Emily Vollans, Ming Fong, Sandy Nakano, Vitali Moiseenko, Moira Schmuland, Roy Ma, Michael McKenzie, Karl Otto, International Journal of Radiation Oncology and Bio Physics, Vol 76, No. 4, pp. 1177-1184

Volumetric Modulated Arc Therapy and Conventional Intensity Modulated Radiotherapy for Simultaneous Maximal Intraprostratic Boost: a Planning Comparison Study. R. Shaffer, W. J. Morris, V. Moiseenko, C. Crumley, S. Nakano, M. Schuland, T. Pickles, K. Otto. Clinical Oncology (2009) 21: 401-407